Skip to Main Content

Paper Details

Decrease in tumor content assessed in biopsies is associated with improved treatment outcome response to pembrolizumab in patients with rare tumors.
J Immunother Cancer
7
2020
PF, Patients, Solid Tumors, TC, biopsies, biopsy, patients, pembrolizumab, proliferative fibrosis, rare tumors, tumors
Author NameAffiliation
Kenneth R HessUniversity of Texas MD Anderson Cancer Center
Kenneth R HessUniversity of Texas MD Anderson Cancer Center
  • 1 - 2

Datasets

Release 1.2